

1 Sensitive detection of Live *Escherichia coli* by bacteriophage amplification-coupled
2 immunoassay on the Luminex[®] MAGPIX instrument

3 Tomotaka Mido^{a*}, Eric M. Schaffer^{b,c}, Robert W. Dorsey^c, Shanmuga Sozhamannan^{d,e}, E.
4 Randal Hofmann^{c,f}

5
6 CBRN Detection Technology Section, CBRN Defense Technology Division, Advanced Defense
7 Technology Center, Acquisition, Technology and Logistics Agency (ATLA), Tokyo, Japan^a;
8 Leidos, Inc., Aberdeen Proving Ground, Maryland, USA^b; Biosciences Division, U.S. Army
9 Edgewood Chemical Biological Center, Aberdeen Proving Grounds, Edgewood, MD, USA^c; The
10 Tauri Group, LLC, Alexandria, VA, USA^d; Defense Biological Product Assurance Office, JPM
11 G, JPEO, Frederick, MD, USA^e; EXCET, Inc. Springfield, VA, USA^f.

12

13 Running Head: Bacterial detection via phage on a MAGPIX instrument

14

15 #Address correspondence to Edward.R.Hofmann.ctr@mail.mil

16 *Present address: International Affairs Office, International Cooperation Division, Department
17 of Equipment Policy, Acquisition, Technology and Logistics Agency (ATLA), Tokyo, Japan

18

19

20

21 **Abstract (250 words)**

22 Phages are natural predators of bacteria and have been exploited in bacterial detection because of
23 their exquisite specificity to their cognate bacterial hosts. In this study, we present a
24 bacteriophage amplification-coupled assay as a surrogate for detecting a bacterium present in a
25 sample. The assay entails detection of progeny phage resulting from infection and subsequent
26 growth inside the bacterium present in suspected samples. This approach reduces testing time
27 and enhances sensitivity to identify pathogens compared to traditional overnight plaque assay.
28 Further, the assay has the ability to discriminate between live and dead cells since phages require
29 live host cells to infect and replicate. To demonstrate its utility, phage MS2 amplification-
30 coupled, bead-based sandwich type immunoassay on the Luminex[®] MAGPIX instrument for
31 *Escherichia coli* detection was performed. The assay not only showed live cell discrimination
32 ability but also a limit of *E. coli* detection of 1×10^2 cells/mL of live cells after a 3-hour
33 incubation. In addition, the sensitivity of the assay was not impaired in the presence of dead
34 cells. These results demonstrate that bacteriophage amplification-coupled assay can be a rapid
35 live cell detection assay compared to traditional culture methods and a promising tool for quick
36 validation of bacterial inactivation. Combined with the unique multiplex bead chemistry afforded
37 by Luminex[®] MAGPIX platform, the phage assay can be expanded to be an ultra-deep multiplex
38 assay for the simultaneous detection of multiple pathogens using specific phages directed against
39 the target pathogens.

40

41

42

43 **Text (3000 words)**

44 **Introduction**

45 Early diagnosis of an etiological agent is paramount in implementing timely and appropriate
46 countermeasures to prevent fatal consequences. In an outbreak scenario, protecting the patients
47 and preventing further dissemination of the disease relies on early, rapid, accurate and sensitive
48 detection of the infectious agent. This in turn relies on the assay and detection platform used.

49 Currently, four broad categories of biodetection systems are available. 1) Microbiological/
50 biochemical tests, 2) antibody based, 3) nucleic acid based and 4) other methods including mass
51 spec and bioluminescence. The length of assay times and levels of purification of the sample to
52 be tested vary widely with these systems. Conventional microbiological culturing and staining,
53 differential growth of target organisms in selective media require live cells and take time
54 anywhere from 16 hours to several days in some cases, prior to definitive identification of the
55 culprit organisms (1).

56 There are some drawbacks with the antibody or nucleic acid based systems. For example, PCR
57 and nucleic acid sequence-based amplification (NASBA) enrich a single specific piece of DNA
58 or RNA sequence up to 10^6 -fold in 20 minutes to a few hours and theoretically have a sensitivity
59 of a single bacterial cell. The PCR methods give rapid, specific detection but are limited by small
60 sample volumes (e.g., 5 μ l for PCR). Furthermore, substances in the sample matrix may inhibit
61 the PCR reaction and the steps used to concentrate the sample to obtain enough templates for
62 PCR may concentrate the inhibitors as well. Immunoassays are based on the concept that any
63 compound that is capable of triggering an immune response can be targeted as an antigen and
64 have been used not only for all types of agents including spores, toxins, and viruses. In general,

65 PCR is much more sensitive than immuno-assays (1). These NASBA and immunoassays cannot
66 discriminate between live and dead target pathogens.

67 There is another paradigm that takes advantage of phages for bacterial detection. Phages are
68 bacterial viruses and are specific to each bacterial species they infect and sometimes, even strains
69 of a given species. The kinetics of interaction between bacteria and their cognate phages is
70 comparable to that of antigen-antibody interaction, making them highly suitable for bacterial
71 detection (2, 3). In addition, the phage-bacterial specificity has evolved over millions of years
72 making them as good as or even better than antigen-antibody specificity. The specificity is
73 attributed to a receptor on the surface of phage that interacts with a receptor on the bacterial
74 surface and this pair is unique. This specificity has been used to develop phage-typing schemes
75 for bacterial species and strains (4-9). Moreover, the cost incurred in producing a phage-based
76 detection reagent is relatively inexpensive compared to the antigen-antibody based reagents. In
77 addition, phages can be useful in deciphering viability of a bacterial pathogen in the sample and
78 furthermore, replication of phage inside the bacterium leads to an amplification of the detection
79 signals thus increasing the sensitivity of the assay.

80 A number of detection systems exploiting phage-bacterial specificity have been developed for
81 different bacteria (10). One of the earliest phage based detection systems involved incorporation
82 of *lux* genes in a mycobacterial phage genome. Expression of the *lux* genes in susceptible
83 mycobacterial cells emitted luminescence signals captured by a handheld Polaroid camera device
84 termed “bronx-box” (11). Similar approaches have been taken for construction of recombinant
85 phages for the detection of *Bacillus anthracis* and *Yersinia pestis* (12, 13). Another elegant
86 fluorescence technique, designed to detect deadly *E. coli O157:H7* bacteria, relied on
87 introducing green fluorescent protein (*gfp*) gene via a bacteriophage. Expression of phage-

88 encoded *gfp* inside the bacterium emits fluorescence that can be measured in a flow cytometer
89 (14). These methods involved extensive genetic manipulation and relatively expensive
90 fluorescent measurement instruments. There are other limitations to this approach: a) level of
91 expression of LUX/GFP is dependent on the phage promoter that controls its expression; b) low
92 photostability of GFP permits fluorescence measurement only for a few seconds to a minute
93 under normal microscopic conditions and therefore, renders the quantitative fluorescence assay
94 difficult in GFP expressed cells. In order to improve the sensitivity and potential for multiplexing,
95 phage-quantum dot assays for rapid high-sensitive detection of bacterial pathogens have been
96 described (15, 16). Although phage-quantum dot approach has certain advantages in
97 multiplexing and increased sensitivity, appropriate instruments for measuring multiplex
98 fluorescence signals are not available and thus are not field deployable.

99 Previous studies have demonstrated the utility of phage amplification coupled-detection assay in
100 a simple platform such as lateral flow immunoassay (LFI) and showed reasonable detection
101 limits (17, 18). Recently, a magnetic bead coupled to phage tail fiber protein has been used as a
102 sensitive tool for detection of *Salmonella* cells (19). Here, we have harnessed phage features with
103 the multiplex capability of MAGPIX platform to develop a phage amplification coupled assay to
104 detect viable bacteria. These features are: 1) The exclusivity of phage infection of live cells; 2)
105 Phage growth following infection resulting in an exponential increase of progeny particles by
106 several orders of magnitude thereby increasing the sensitivity of the assay; 3) The relatively
107 rapid nature of the assay compared to traditional plaque assay or even conventional culture
108 methods. 4) An unparalleled multiplex capability offered by MAGPIX platform because of its
109 unique bead chemistry (20). As a proof of concept, we describe a MAGPIX bead based sandwich
110 type immunoassay, hereafter referred as phage MAGPIX assay, using phage MS2 and anti MS2

111 antibodies as a surrogate for the detection of *E. coli*. Infection, subsequent replication and growth
112 of MS2 inside *E. coli* present in a sample results in the release of increased number of (several
113 orders of magnitude) progeny MS2 particles, which are captured by the anti MS2 antibody
114 coupled to MAGPIX beads. A secondary (detector) anti-MS2 antibody is added to the complex
115 followed by an additional incubation with streptavidin-coated phycoerythrin (SAPE). The
116 resulting fluorescence of the complex is measured and reported as an indicator of the specific
117 bacteria present in the sample.

118 **Results**

119 **Determination of assay linearity of phage MS2 based MAGPIX immunoassay**

120 The capture sandwich immunoassay for MS2 phage on the MAGPIX platform was developed
121 using polyclonal anti MS2 antibodies. In the assay, target antigen (MS2) is captured by
122 antibodies (anti MS2 antibodies) coupled on the surface of beads, followed by quantification of
123 the bead bound complex by labeled antibodies. Thus, an increase in progeny phage; i.e., phage
124 amplification can be correlated with amplification in fluorescence signal. The concept of using
125 MAGPIX instrument for this assay is illustrated in Figure 1.

126 The phage MAGPIX assay, as an indirect measurement of bacterial detection, is incumbent upon
127 detection of progeny phages rather than the input phage used to initiate infection. Therefore, the
128 input phage concentration should be low enough (below the detection limits of the instrument) so
129 that upon phage amplification there is high enough phage titer to result in significant signal
130 amplification that can be detected. Also, it should not be too low, in which case the assay would
131 require longer incubation times to produce high enough phage titers that would generate
132 measureable fluorescence signal intensities. In order to determine the appropriate initial MS2

133 concentration, the linearity of the MS2 MAGPIX assay was assessed. A dose response curve of
134 the assay was generated by serial dilution of MS2 in LB media and measuring the median
135 fluorescence intensity (MFI). A clear linearity of signal intensity was seen at phage
136 concentrations ranging from 1×10^6 pfu/ mL to 1×10^9 pfu/ mL (Figure 2). Thus, initial MS2
137 concentration to assess the signal amplification in the assay based on phage replication was
138 determined to be 1×10^6 pfu/mL.

139 **Determination of the live cell discrimination ability of phage MAGPIX immunoassay**

140 In order to evaluate the utility of MS2 amplification-coupled assay for *E. coli* detection, initially,
141 live cell discrimination ability of the assay was assessed. Live cells or heat inactivated *E. coli*
142 cells at a concentration of 1×10^6 cells/mL were infected with MS2 at a multiplicity of infection
143 of 1 (1×10^6 pfu/mL) and incubated for 18 hours and the resulting phage particles were analyzed
144 by MS2 MAGPIX immunoassay. The results showed that live cells infected with MS2 amplified
145 fluorescence signal intensity almost 1000 fold at the end of the incubation period whereas dead
146 cells or live cells without the addition of MS2 did not (Figure 3) indicating the ability of the
147 assay to detect live cells as opposed to dead cells.

148 **Establishing the limit of detection and incubation time for the MS2 MAGPIX assay**

149 Having established the live bacterial detection using the MS2 MAGPIX assay, next we
150 investigated the sensitivity (limits of detection of *E. coli*) of the assay, and the minimal
151 incubation time required for making a positive call in the assay. Signal amplification (as
152 indicated by MFI) of the assay in the presence of varying concentrations of live *E. coli* ($0-10^6$
153 cells/ml) was followed from 0 to 3 hours of incubation. The results indicated that with increasing
154 concentrations and incubation times there was a corresponding increase in the signal intensities

155 (Figure 4). Furthermore, the MFI was increased significantly in samples containing *E. coli* at
156 1×10^2 cells/mL after 3-hour incubation and thus establishing a limit of detection for this assay.
157 The limit of detection is defined by a signal greater than the mean background MFI plus three
158 standard deviations. Higher concentrations of *E. coli* (10^5 - 10^6 CFU/ml) produced signal
159 intensities that allowed detection in shorter incubation times; i.e., 1 hour where almost 9-fold
160 increase was observed with 10^5 cells/ml compared to 10^3 cells/ml.

161 **Determination of MS2 phage binding selectivity between live and dead cells using**
162 **MAGPIX assay**

163 When bacterial samples are inactivated, it is difficult to assess complete inactivation by NASBA
164 or immunoassay because dead bacteria still contain nucleic acids or immunoassay targets
165 (epitopes) that are reactive to the respective assays. On the other hand, since phage
166 amplification-coupled assay require live bacteria, it can be a valuable tool for validation of
167 complete inactivation. However, incomplete inactivation may result in samples containing both
168 live and dead cells. In this case, phage can potentially bind to both dead and live cells. Phage
169 binding to dead cells can competitively inhibit binding to live cells (i.e., reducing the number of
170 phages available for infecting live cells) and thereby reduce the sensitivity of the assay. To
171 investigate if MS2 can selectively bind to live cells in the presence of dead cells, MS2 phage
172 MAGPIX assay was performed in the presence varying concentrations of live cells (0 - 10^6
173 cells/ml) or live and dead cells at the same concentrations (0 - 10^6 cells/ml) for one hour. The
174 results indicated that the signal intensities (as MFI) between the groups are very comparable
175 indicating that the presence of dead cells did not affect the infection, replication and growth of
176 live bacteria present in the sample (Figure 5). This result indicates that MS2 selectively bound to
177 only living cells in the presence dead cells.

178

179 **Discussion**

180 An ideal bioagent detection technology/platform would have the following desirable properties:

181 The detection assays must have the potential for rapid, reproducible, high-sensitive (detection at

182 very low concentrations of the agent), high-specific (high true positive/true negative and low

183 false-positive/ low false-negative) detection of agents (conventional as well as uncharacterized or

184 genetically modified agents) directly from complex matrix samples with minimal false results,

185 capable of detecting low concentrations of target agents without interference from background

186 materials. Also, the platform to conduct the assays should be user-friendly, portable and a point

187 of care or field device that is capable of detecting multiple agents simultaneously in a high

188 throughput manner (processing hundreds of samples) in any matrix type (clinical or

189 environmental). Additionally it is highly desirable to have a flexible technology with an open

190 architecture; amenable for a plug and play format to develop new assays rapidly and, above all,

191 the technology should be inexpensive. Although several of the currently available commercial

192 detection platforms provide many of the desired features, no one system can satisfy all of these

193 criteria.

194 Many of the current rapid detection technologies are based either on PCR or some form of an

195 immunoassay such as lateral flow immunoassay. The major drawback of these methods is that

196 they cannot discriminate whether the suspected sample contains live or dead bacteria. This

197 discrimination is critical especially in a biothreat/ biosurveillance scenarios not only for making

198 correct courses of action but also for verifying if decontamination activities were successful.

199 Also, in a clinical or point of care/field setting such a discrimination ability and phage mediated

200 signal amplification will be very useful for determining antibiotic sensitivity rapidly. For

201 example, in slow growing bacteria like *Mycobacterium* spp such an approach has been used to
202 test antibacterial susceptibility in the field (11). Also, these technologies are limited in their
203 potential for multiplexing and high throughput analysis. To address these two gaps, as a proof of
204 concept, we developed a phage based live agent detection assay using MAGPIX instrument.
205 Phage MS2 is an *E. coli* male specific phage because of its specificity to infect only strains that
206 carry the F pilus (21). MS2 has a burst size of 5000-10000 per infected cell (22) and a short burst
207 time of 30 minutes (23). In this study, MS2 amplification-coupled MAGPIX immunoassay was
208 performed to demonstrate utility of bacteriophage amplification-coupled immunoassay for *E.*
209 *coli* detection. Essentially, in this assay, progeny particles resulting from infection of bacteria in
210 a sample are detected and reported as an indicator of the pathogen present. We found a
211 sensitivity of 1×10^4 cells/ml of *E. coli* and selective binding to live cells and no inhibition in the
212 presence of dead bacteria after a one hour incubation. This limit of detection is quite comparable
213 to published immunoassays for *E. coli* detection (24, 25). The limit of detection of this assay is
214 dependent on the burst size of a given phage in its specific bacterial host. Phages with high burst
215 will yield large number of progeny particles that will yield correspondingly high signal intensity
216 in the MAGPIX assay. However, for phages with low burst size, a large number of bacteria
217 should be present during initial infection, in order to yield high enough signal intensity above the
218 background to make a positive call. The optimal multiplicity of infection needs to be determined
219 for each phage-bacterium combination since the initial bacterial load in each sample may vary.
220 Intuitively, it would seem phage-based assays are not available for other types of agents such as
221 spores, viruses and toxins. However, using M13 like phages, one can pan for phages with peptide
222 displays that bind specifically to these biothreats and add that to the MAGPIX panel of assays.

223 Despite these limitations, our future efforts will focus on developing a phage multiplex MAGPIX
224 assay panel to target bacterial, viral and toxin threats.

225 **2. Materials and Methods**

226 **2.1. Phage stock**

227 MS2 phage and *E. coli* strain C-3000 (ATCC [15597](#)) used in this study were obtained from
228 Brouns lab, Delft University of Technology (NL). The phage stock was prepared from the seed
229 stock in small scale liquid culture using established laboratory procedures (26)

230 **2.2. MAGPIX immunoassay development**

231 Polyclonal antibodies provided by Defense Biological Product Assurance Office (DBPAO);
232 Rabbit anti- MS2 (Rab α -MS2: ABE#120, J-291100-02) were used to develop the capture
233 sandwich assay on the MAGPIX platform (Luminex, Austin, TX). Antibodies were immobilized
234 on MagPlex carboxylated microspheres (Luminex, Austin, TX) at 5pg antibody/ microsphere
235 using the carbodiimide coupling protocol provided by the manufacturer. To conduct the coupling,
236 0.1 M Sodium Phosphate monobasic (pH6.2 \pm 0.2) was used for washing beads and incubation.
237 Microspheres were then washed and resuspended in 0.01M PBS (pH7.4 \pm 0.1) with
238 0.05% Tween20. Antibodies immobilize on microsphere were used as the capture in the assay.
239 Antibodies were also biotinylated using a 30-fold molar excess of BT-LCLC-NHS (Thermo
240 Scientific, Rockford, IL) as the detection element with a streptavidin-phycoerythrin conjugate
241 (SAPE) serving as the tracer molecule.

242 **2.3. MAGPIX immunoassay procedure**

243 2500 microspheres per well of antibody coated microspheres were incubated for 1 hour with
244 samples. Following incubation, the sample was, washed, and then incubated with 4µg/mL
245 biotinylated antibody for 30 minutes. The microspheres were washed again and then incubated
246 with 4µg/mL SAPE to generate the fluorescent complex. After a final wash and re-suspending in
247 100µL of wash buffer, the assay results were evaluated using the MAGPIX instrument.
248 Incubations were performed at room temperature, at 800rpm, and protected from light. Samples
249 were washed twice with 100µL of wash buffer (0.01M PBS with 1%BSA and 0.05%sodium
250 azide, pH7.4).

251 **2.4. MS2 amplification-coupled MAGPIX immunoassays**

252 MS2 amplification-coupled MAGPIX immunoassays were performed on the MAGPIX platform.
253 Prior to MAGPIX immunoassay, MS2 and *E.coli* (Delft University of Technology, NL) diluted
254 in LB media were incubated at 37 °C shaking at 300 rpm for respective time. E-coli
255 concentration (cells/mL) was calculated by OD₆₀₀ based on the formula as OD₆₀₀ of 1.0 = 8×10^8
256 cells/mL. To prepare near 100% of live cells, live E-coli used in this study was incubated to keep
257 OD₆₀₀ below 1.0 after inoculating. When dead cells were used, *E.coli* was inactivated by heating
258 over 95°C in water bath for 15 min prior to the OD₆₀₀ measurement. Incubated samples were
259 analyzed by MAGPIX assay.

260 **Acknowledgements**

261 We would like to thank Dr. Stan JJ Brouns and Franklin Nobrega (Delft University of
262 Technology, Netherlands) for the kind gift of MS2 phage and the *E. coli* strain used in the assay.
263 T. Mido was supported by the Japan Ministry of Defense – US Army Engineer and Scientist
264 Exchange Program. Funding for this work was provided the Defense Biological Product

265 Assurance Office, Joint Program Manager Guardian, Joint Program Executive Office for
266 Chemical Biological Defense.

267 **Appendixes**

268 **References**

- 269 1. Lim DV, Simpson JM, Kearns EA, Kramer MF. 2005. Current and developing technologies for
270 monitoring agents of bioterrorism and biowarfare. *Clin Microbiol Rev* 18:583-607.
- 271 2. Moldovan R, Chapman-McQuiston E, Wu XL. 2007. On kinetics of phage adsorption. *Biophys J*
272 93:303-15.
- 273 3. Reverberi R, Reverberi L. 2007. Factors affecting the antigen-antibody reaction. *Blood Transfus*
274 5:227-40.
- 275 4. Engel HW, Berwald LG, Grange JM, Kubin M. 1980. Phage typing of *Mycobacterium kansasii*.
276 *Tubercle* 61:11-9.
- 277 5. Ward LR, de Sa JD, Rowe B. 1987. A phage-typing scheme for *Salmonella enteritidis*. *Epidemiol*
278 *Infect* 99:291-4.
- 279 6. Loessner MJ. 1991. Improved procedure for bacteriophage typing of *Listeria* strains and
280 evaluation of new phages. *Appl Environ Microbiol* 57:882-4.
- 281 7. Chattopadhyay DJ, Sarkar BL, Ansari MQ, Chakrabarti BK, Roy MK, Ghosh AN, Pal SC. 1993. New
282 phage typing scheme for *Vibrio cholerae* O1 biotype El Tor strains. *J Clin Microbiol* 31:1579-85.
- 283 8. Abshire TG, Brown JE, Ezzell JW. 2005. Production and validation of the use of gamma phage for
284 identification of *Bacillus anthracis*. *J Clin Microbiol* 43:4780-8.
- 285 9. Rees CE, Dodd CE. 2006. Phage for rapid detection and control of bacterial pathogens in food.
286 *Adv Appl Microbiol* 59:159-86.
- 287 10. Petty NK, Evans TJ, Fineran PC, Salmond GP. 2007. Biotechnological exploitation of
288 bacteriophage research. *Trends Biotechnol* 25:7-15.
- 289 11. Hazbon MH, Guarin N, Ferro BE, Rodriguez AL, Labrada LA, Tovar R, Riska PF, Jacobs WR, Jr. 2003.
290 Photographic and luminometric detection of luciferase reporter phages for drug susceptibility
291 testing of clinical *Mycobacterium tuberculosis* isolates. *J Clin Microbiol* 41:4865-9.
- 292 12. Schofield DA, Westwater C. 2009. Phage-mediated bioluminescent detection of *Bacillus*
293 *anthracis*. *J Appl Microbiol* 107:1468-78.
- 294 13. Schofield DA, Molineux IJ, Westwater C. 2009. Diagnostic bioluminescent phage for detection of
295 *Yersinia pestis*. *J Clin Microbiol* 47:3887-94.
- 296 14. Oda M, Morita M, Unno H, Tanji Y. 2004. Rapid detection of *Escherichia coli* O157:H7 by using
297 green fluorescent protein-labeled PP01 bacteriophage. *Appl Environ Microbiol* 70:527-34.
- 298 15. Edgar R, McKinsty M, Hwang J, Oppenheim AB, Fekete RA, Giulian G, Merrill C, Nagashima K,
299 Adhya S. 2006. High-sensitivity bacterial detection using biotin-tagged phage and quantum-dot
300 nanocomplexes. *Proc Natl Acad Sci U S A* 103:4841-5.
- 301 16. Yim PB, Clarke ML, McKinsty M, De Paoli Lacerda SH, Pease LF, 3rd, Dobrovolskaia MA, Kang H,
302 Read TD, Sozhamannan S, Hwang J. 2009. Quantitative characterization of quantum dot-labeled
303 lambda phage for *Escherichia coli* detection. *Biotechnol Bioeng* 104:1059-67.
- 304 17. Cox CR, Jensen KR, Mondesire RR, Voorhees KJ. 2015. Rapid detection of *Bacillus anthracis* by
305 gamma phage amplification and lateral flow immunochromatography. *J Microbiol Methods*
306 118:51-6.

- 307 18. Stambach NR, Carr SA, Cox CR, Voorhees KJ. 2015. Rapid Detection of *Listeria* by Bacteriophage
308 Amplification and SERS-Lateral Flow Immunochromatography. *Viruses* 7:6631-41.
- 309 19. Denyes JM, Dunne M, Steiner S, Mittelviehhaus M, Weiss A, Schmidt H, Klumpp J, Loessner MJ.
310 2017. Modified Bacteriophage S16 Long Tail Fiber Proteins for Rapid and Specific Immobilization
311 and Detection of *Salmonella* Cells. *Appl Environ Microbiol* 83.
- 312 20. Mukherjee S, Katki K, Arisi GM, Foresti ML, Shapiro LA. 2011. Early TBI-Induced Cytokine
313 Alterations are Similarly Detected by Two Distinct Methods of Multiplex Assay. *Front Mol*
314 *Neurosci* 4:21.
- 315 21. Friedman SD, Genthner FJ, Gentry J, Sobsey MD, Vinje J. 2009. Gene mapping and phylogenetic
316 analysis of the complete genome from 30 single-stranded RNA male-specific coliphages (family
317 *Leviviridae*). *J Virol* 83:11233-43.
- 318 22. Fiers W, Contreras R, Duerinck F, Haegeman G, Iserentant D, Merregaert J, Min Jou W,
319 Molemans F, Raeymaekers A, Van den Berghe A, Volckaert G, Ysebaert M. 1976. Complete
320 nucleotide sequence of bacteriophage MS2 RNA: primary and secondary structure of the
321 replicase gene. *Nature* 260:500-7.
- 322 23. Strauss JH, Jr., Sinsheimer RL. 1967. Characterization of an infectivity assay for the ribonucleic
323 acid of bacteriophage MS2. *J Virol* 1:711-6.
- 324 24. Kim JS, Anderson GP, Erickson JS, Golden JP, Nasir M, Ligler FS. 2009. Multiplexed detection of
325 bacteria and toxins using a microflow cytometer. *Anal Chem* 81:5426-32.
- 326 25. Clotilde LM, Bernard Ct, Hartman GL, Lau DK, Carter JM. 2011. Microbead-based immunoassay
327 for simultaneous detection of Shiga toxins and isolation of *Escherichia coli* O157 in foods. *J Food*
328 *Prot* 74:373-9.
- 329 26. Strauss JH, Jr., Sinsheimer RL. 1963. Purification and properties of bacteriophage MS2 and of its
330 ribonucleic acid. *J Mol Biol* 7:43-54.

331

332 Figure 1. Illustration of bacteriophage amplification-coupled immunoassay for bacterial
333 detection on MAGPIX instrument. (A) Phage infection of a bacterial cell and subsequent growth
334 inside the bacterium results in host cell lysis and release of progeny phage in large numbers. (B)
335 Antibody coupled on the surface of magnetic bead captures input and progeny phage. (C)
336 Addition of detector antibody followed by (D) an incubation with SAPE. The fluorescence
337 emitted by the final complex is measured in the MAGPIX instrument and reported as relative
338 fluorescence units.

339

340 Figure 2. Assay linearity of MS2 MAGPIX immunoassay detection. Sandwich type MAGPIX
341 immunoassay for MS2 detection was performed at respective MS2 concentrations. Vertical axis

342 shows the median fluorescence intensity (MFI). Values are average of two independent
343 measurements of two replicates each.

344

345 Figure 3. Validation of live cell discrimination ability of MS2 amplification coupled assay
346 MS2 amplification-coupled MAGPIX immunoassay for *E. coli* detection was performed.
347 Samples were incubated for 18 hours prior to analysis on the MAGPIX instrument. Vertical axis
348 shows the median fluorescence intensity (MFI). The data in this figure is based upon 2 separate
349 run of 2 replicates.

350

351 Figure 4. Determination of the limit of detection and incubation time for MS2 phage MAGPIX
352 assay. Signal intensity of MS2 amplification-coupled MAGPIX immunoassay for *E. coli*
353 detection was tracked from 0 to 3 hours. Samples containing 1.0×10^6 PFU/mL of MS2 and live
354 cells at varying concentrations from $0-1 \times 10^6$ CFU/ml were incubated for indicated times prior
355 to analysis on the MAGPIX instrument. Vertical axis shows the median fluorescence intensity
356 (MFI) and each data point is the average of 2 replicates of 2 separate assays.

357

358 Figure 5. Determination of MS2 phage binding selectivity between live and dead cells using
359 MAGPIX assay. Signal intensity of MS2 amplification-coupled MAGPIX immunoassay for *E.*
360 *coli* detection was compared between sample containing only living cells and sample containing
361 live cells and dead cells. Samples containing 1.0×10^6 pfu/mL MS2 and live cells at respective
362 concentration were incubated with/without 1.0×10^6 cells/mL inactivated cells for 1 hour prior to

363 the immunoassay. Vertical axis shows the median fluorescence intensity (MFI). The values
364 represent average of two separate runs with 2 replicates each.

365

366





Figure 2




Figure 3




Figure 4




Figure 5

